VER and Elan expand frovatriptan deal

Vernalis (LES:VER) and partner ELN expanded their marketing deal for VER's frovatriptan 5HT1B/1D agonist for migraine to include additional studies of the

Read the full 221 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE